Clinical trial · Interventional
Impact of Bladder Depletion on Mesorectal Movements During Radiotherapy in Rectal Cancer
NCT04323722CI-TRIAL-00115521MESORECT-VVcompletedN/AResults postedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This trial is assessing how Bladder filling variations and thus mesorectal movements are less when radiotherapy treatment is received with an empty bladder in rectal cancer
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Rectal Cancer | Malignant Rectal Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Empty Bladder pCT and CBCTs | Procedure | — | UNRESOLVED |
| Full Bladder pCT and CBCTs | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- OTHER
- label
- Empty and full bladder
- description
- pCT and CBCTs in empty and full bladder conditions
- interventionNames
- Procedure: Empty Bladder pCT and CBCTs
- Procedure: Full Bladder pCT and CBCTs
Primary outcomes (1)
- measure
- Difference Between the Mesorectal Anterior Distance Measured on the pCT and the Distance Measured on Each CBCT, at Different Heights Set on Bone Landmarks.
- timeFrame
- 5 weeks
- description
- The mesorectal anterior distance was measured on planning pCT and on each CBCT at predefined heights based on bone landmarks. Differences between pCT and CBCT measurements were assessed.
Secondary outcomes (2)
- measure
- Differences in Bladder Volumes During Treatment (CBCTs) Compared to pCT
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Histologically confirmed rectal adenocarcinoma * T2 N+ or T3 any N, eligible for radiotherapy or neo-adjuvant radio-chemotherapy treatment in a long course of 25 fractions * Performance Status less or equal to 2 * Male or female 18 Years and older * Creatinine clearance greater than or equal to 50ml/min * Fertile patients must use effective contraception * Written informed consent * Patient must be affiliated to a Social Health Insurance Exclusion Criteria: * Previous treatment with pelvic radiotherapy * Chronic inflammatory bowel disease in flare-up. * Urinary catheterization, urinary diversion or cystectomy * Hip prosthesis * History of prostatectomy, or hysterectomy * Urinary incontinence \> 2 * Pregnant or nursing patient * Persons deprived of their liberty, as well as adults subject to a legal protection measure * Impossibility to submit to the medical follow-up of this clinical trial for geographical, social or psychological reasons
References
Publications (0)
Data not yet available
No reference posted for this study.